Pfizer Monthly Obesity Shot Shows Favorable Trial Data
Pfizer presented midstage trial data for its monthly obesity drug berobenatide showing a side-effect profile comparable to Novo Nordisk's weekly Wegovy injection. The study reported weight loss of up to 12.3 percent and nausea rates within investor expectations as the company prepares for late-stage programs.
Xurve View
Insights:
Xurve View
PFIZER INC reported on Saturday that its experimental monthly obesity injection, berobenatide, achieved up to 12.3% weight loss in mid-stage trial patients. The results position the drug as a viable monthly alternative to weekly treatments currently dominating the metabolic market. Success is critical for PFIZER INC after it was forced to discontinue two previous weight-loss candidates due to liver safety concerns.
